Press releases
27-Jun-2025
UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder
20-Jun-2025
UCB to present new data from its neurology portfolio at the 11th European Academy of Neurology (EAN) Congress 2025
16-Jun-2025
Transparency notification FMR LLC
12-Jun-2025
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
12-Jun-2025
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
12-Jun-2025
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activit
11-Jun-2025
BIMZELX[®]▼(bimekizumab) three-year data at EULAR 2025 showed lasting efficacy and control of inflammation in psoriatic arthritis and axial spondyloarthritis
19-May-2025
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
13-May-2025
UCB presents expansive data set at 15th Myasthenia Gravis Foundation of America (MGFA) International Conference highlighting commitment to advancing gMG treatment outcomes and experiences
09-May-2025
RYSTIGGO[®] (rozanolixizumab) receives approval in Japan for two new administration methods as UCB begins ONWARD program for patient support
24-Apr-2025
UCB’s General Meeting of Shareholders 2025
11-Apr-2025
Global data show real-world effectiveness of romosozumab for patients at high fracture risk
05-Apr-2025
Acquisition of own shares
04-Apr-2025
Acquisition of own shares
03-Apr-2025
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
01-Apr-2025
UCB presents key data from Alzheimer’s and Parkinson’s disease research programs at AD/PD 2025
28-Mar-2025
Acquisition of own shares
21-Mar-2025
Acquisition of own shares
19-Mar-2025
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
14-Mar-2025
Acquisition of own shares
12-Mar-2025
Transparency notification BlackRock, Inc.
11-Mar-2025
Transparency notification BlackRock, Inc.
07-Mar-2025
Share Repurchase Program 2025 to cover UCB's Long Term Incentive Plans for employees
07-Mar-2025
BIMZELX[®] (bimekizumab-bkzx) two-year data at AAD showed potential to eliminate draining tunnels in hidradenitis suppurativa (HS), and reduction in disease burden
07-Mar-2025
BIMZELX[®] (bimekizumab-bkzx) five-year data at AAD 2025 showed sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis
07-Mar-2025
BIMZELX[®][ ](bimekizumab-bkzx) two-year data at AAD showed potential to eliminate draining tunnels in hidradenitis suppurativa (HS), and reduction in disease burden
27-Feb-2025
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
12-Feb-2025
BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS)
31-Jan-2025
RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods
15-Jan-2025
UCB showcases decade of growth and Patient Value Strategy driving differentiated innovation
09-Jan-2025
UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform
02-Jan-2025
Transparency notification Wellington